CliffBio
biologic

Afrezza

insulin human

Loss of exclusivityApril 2027projected — 12-year biologic exclusivity estimate
CompanyMannKind Corporation →See this company's full patent-cliff portfolio

Drug detail

Brand nameAfrezza
Active ingredientinsulin human
Strength12UNITS/INH
Dosage formPowder
RouteInhalation
ModalityBiologic
FDA approvalApril 2015
Marketing statusRx

More from MannKind Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Afrezza patent cliff — loss of exclusivity April 2027 | CliffBio